Antioxidant treatment in Spielmeyer-Sjögren's disease.
The data for 125 patients with Spielmeyer-Sjögren's disease is presented. Antioxidant therapy was given to 49. 27 received a combination of vitamin E, vitamin C, methionine and BHT. As the disease began to progress, the treatment was changed to a combination of sodium selenite and vitamin E in 14 of the 27 patients. The same therapy was also given to 22 children who had not received previous antioxidant supplementation. The number of positive and negative responses was nearly equal in the 2 treatment groups. However, the quality of the response was better in the selenite group and it has been possible in some cases to stop for several years, at least, the deterioration which began during the original therapy.
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002084:Butylated Hydroxytoluene / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D004569:Electroencephalography; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007360:Intelligence / Q000187:drug effects; D008297:Male; D008715:Methionine / Q000627:therapeutic use; D009472:Neuronal Ceroid-Lipofuscinoses / Q000188:drug therapy* / Q000523:psychology; D009483:Neuropsychological Tests; D020887:Selenious Acid; D012643:Selenium / Q000097:blood / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D014810:Vitamin E; D002084:Butylated Hydroxytoluene; D008715:Methionine; D020887:Selenious Acid; D012643:Selenium; D001205:Ascorbic Acid